Electrokare: ECG-based physiology models for clinical and performance use

Electrokare is building a physiology model that reads the body through signals it already produces, starting with the ECG. Its intended buyers are clinicians, health-system partners and performance teams that want more useful measurements from continuous or existing cardiac signals—not consumers looking for a diagnosis from a landing page.

What it does

The current Electrokare site describes Nefesh as an ECG foundation model and presents two product arms: Electrokare Clinical and Electrokare Performance. It says the platform is trained and validated on more than 3M patients and actively deployed to 40K-plus patients. The site links to a clinical evidence pathway and says the model is intended for precision, preventative medicine and human performance.

The product thesis is to infer changes that are difficult to measure non-invasively today, including cardiac function, valve changes or physiological stress. Those are company-described capabilities and product direction, not a clinical conclusion about any individual. The public pages do not publish a complete regulatory status, reimbursement model or price.

Why I’d look closer

The advantage is reusing a familiar signal instead of asking people to adopt another invasive test or wearable. The buyer could be a clinical partner, device company, health system or performance program that can define a safe decision boundary around the model output.

The tradeoff is medical validation. A model trained on millions of patients can still perform differently across devices, populations, care settings and disease prevalence. If a result changes care, the clinician needs the evidence, calibration, false-positive cost and escalation path—not only a precise-looking number.

What I’d ask

Which measurements are clinically validated, in which populations and on which ECG hardware? What is the intended-use and regulatory status of Clinical versus Performance? Can a clinician inspect confidence, provenance and drift? How are patient data, consent, retention and model updates handled? What happens when the signal is noisy or outside the training distribution?

My editorial take

Shortlist Electrokare for a clinical-evidence or performance-partnership conversation if ECG data is already available and the use case has a clear human decision-maker. Treat the model as decision support until regulatory and clinical evidence say otherwise. The product’s opportunity is making a low-friction signal more informative; its burden is proving that the extra information is safe to act on.

Quick facts

Field	Sourced detail
Product	ECG foundation model with clinical and performance applications
Buyer	Clinicians, health systems, medical-device and human-performance partners
Company-reported scale	3M+ patients trained/validated; 40K+ actively deployed
Pricing/status	Pricing and complete regulatory status not published in checked pages
Main question	Which model output is validated enough to influence a real clinical or performance decision?

Sources checked

Source	Checked
Electrokare Speedrun profile	2026-09-19
Electrokare homepage	2026-09-19
Electrokare model page	2026-09-19